ARTEMIS Precision Targeting
Focal HIFU for Prostate
SonaCare Medical has developed the next generation system for the treatment of localized prostate cancer. Sonablate 500 HIFU surgical ablation system delivers precise and focused ablative therapy with the possibility of vastly reduced side effect profile.
- Published clinical results
- Automatic treatment planning
- Minimally invasive procedure
- Unmatched accuracy
- Real-time imaging
- Multimodal platform
- Intuitive user interface
- Transportable
Robotic Focal Features:
1. AIM
Image Guided Planning
Sonablate 500 allows users to target specific regions of interest within the prostate using Sonablate’s integrated ultrasound imaging, MRI/US fusion, sophisticated planning and monitoring tools. Our Sonablate fusion software allows segmented and annotated DICOM radiology images to be imported and fused with live ultrasound images acquired with the Sonablate probe.
2. ABLATE
Precise Tumor Ablation and Tissue Spearing
Sonablate 500 allows users to precisely ablate targeted tumors with pinpoint accuracy while sparing untargeted tissue and vital structures. Sound energy passes through intervening untargeted tissue to create a focal “shot” of ablation 10 mm by 3 mm by 3 mm in size. A series of shots are combined to cover the tissue targeted for ablation.
3. ANALYZE
Continuous Tissue Change Monitoring
Sonablate 500 HIFU tissue destruction is tracked using real-time ultrasound imaging along with advanced Tissue Change Monitoring (TCM) software. TCM is a unique, quantitative software module that displays real-time changes occurring in prostate tissue ablated with HIFU. Rather than depicting changes in temperature, TCM provides a direct assessment of the degree of tissue destruction.
Robotic transducer movement ~ Adjustable water bolus
Published Clinical Results:
Focal Prostate HIFU with Sonablate 500.
University College London Focal HIFU Studies utilizing the Sonablate 500 system
Primary Hemi HIFU
“Focal Therapy for Localized Prostate Cancer: A Phase I/II Trial.” The Journal of Urology 185, no. 4 (April 2011): 1246–1255.
Ahmed, H.U., Freeman, A., Kirkham, A.P., Sahu, M., Scott, R., Allen, C., Van der Meulen, J., and Emberton, M.
Primary Multifocal HIFU
“Focal Therapy for Localised Unifocal and Multifocal Prostate Cancer: a Prospective Development Study.” The Lancet Oncology 13, no. 6 (June 2012): 622–632.
Ahmed, H.U., Hindley, R.G., Dickinson, L., Freeman, A., Kirkham, A.P., Sahu, M., Scott, R., Allen, C., Van der Meulen, J., Emberton, M.
Primary Index Lesion HIFU
“Focal Ablation Targeted to the Index Lesion in Multifocal Localised Prostate Cancer: A Prospective Development Study.” European Urology (2015).
Ahmed, H.U., Dickinson, L., Charman, S., Weir, S., McCartan, N., Hindley, R.G., Freeman, A., Kirkham, A.P., Sahu, M., Scott, R., Allen, C., Van der Meulen, J., Emberton, M.